Sickle Cell Disease (SCD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Sickle Cell Disease (SCD) Emerging Therapy and TPP Insights Thelansis’s “Sickle Cell Disease (SCD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Sickle Cell Disease (SCD) Overview Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a glutamic acid to valine substitution at position 6 of the beta-globin chain, yielding abnormal hemoglobin S that polymerizes under deoxygenated conditions to drive erythrocyte sickling, hemolytic anemia, and vaso-occlusion. Hallmarks include severe episodic vaso-occlusive crises (VOCs), acute chest syndrome, stroke, and cumulative multiorgan damage. Diagnosis is established via universal newborn screening using hemoglobin electrophoresis or HPLC. Hydroxyurea remai...